PituitaryHumansDenosumabBone DensityFemaleMale
Long-term effect on bone mineral density of denosumab in the treatment of hyperpituitarism driven osteoporosis: an exploratory study.
Sabrina Chiloiro, Flavia Costanza, Alessandra Vicari, Antonella Giampietro, Chiara Palumbo, Amato Infante, Consolato Gulli, Mario Rigante, Pier Paolo Mattogno, Laura De Marinis, Alessandro Olivi, Antonio Bianchi, Francesco Doglietto, Andrea Giustina, Alfredo Pontecorvi
Published: 202610.1007/s11102-025-01630-0
Abstract
BACKGROUND: Treatment of skeletal fragility in patients with pituitary diseases is challenging. Denosumab, an antiresorptive bone active drug, increased bone mineral density (BMD) and reduced incidence and risk of fractures in primary osteoporosis. T…
Preview only. Read the full abstract at the source